Myeloid Therapeutics is an immunology company focused on combining immunologic insights with cutting-edge technologies to harness myeloid cells to eradicate cancer and other diseases. The Company's ATAKTM platform technology can be broadly applied, and it is initially advancing a cell therapy program for T cell lymphoma and a primed monocyte approach to treat glioblastoma. The ATAK platform is scalable to multiple treatment modalities and other disease areas in collaboration with partners.
Pretzel was founded by some of the world’s foremost academics in mitochondrial biology, and we benefit from the leadership of accomplished experts in drug discovery, drug development, and company formation. Our name is inspired by the focal point of our science, the mitochondrion, whose highly folded inner membrane is one of many fascinating features that make it unlike any other organelle in the body.
Disruption in healthcare is accelerated by the need for improved diagnostics, novel pharmaceutical therapies, and the shift to patient-centric solutions. With the mission to tackle the massive oncology dilemma, Elephas is leading the way to change how clinicians treat cancer patients. By harnessing the latest advances in cancer biology, multimodal microscopy, and artificial intelligence, the Elephas platform has the ability to empower clinical decision-making and accelerate drug development.
Vizgen is a privately held biotech company developing the next generation of spatially resolved, single-cell transcriptomics technology and toolbox. The company's patented MERFISH technology enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and detection efficiency at subcellular resolution.
Remix Therapeutics is a biotechnology business that is working on developing small-molecule medicines to reprogram ribonucleic acid processing and cure disease in novel ways. The company's medicines aid in the identification of patterns in ribonucleic acid processing and their application to control gene expression in order to change the way genes are read from the genome, correcting, enhancing, or eliminating the gene message, allowing healthcare practitioners to address disease causes at their source.
Pheast Therapeutics is a cancer immunotherapy company focused on developing novel checkpoint therapies to harness the innate immune system in the fight against cancer. It was founded in 2020 and headquartered in Palo Alto, California.
Be Biopharma pioneers engineered B cell medicines aimed at improving treatments for conditions like Hemophilia B and cancer. Their innovative approach utilizes precision genome editing to create durable and effective cell therapies.
Recuro Health delivers value throughout the healthcare ecosystem with an integrated digital health solution that transitions the U.S. healthcare system from a reactive, disease-focused model to a population health, outcomes approach. Digital Medical Home can be tailored to specific healthcare requirements. They offer fundamental virtual care services such as primary care, behavioral health, and urgent care.
LifeMine Therapeutics combines genomics with AI and synthetic biology to discover and develop a pipeline of novel medicines. LifeMine’s Avatar-Rx platform integrates high-throughput microbiology, data science and machine learning, genome engineering, and automation technologies to search the fungal biosphere for novel GEMs having a predetermined target and biological function. The platform integrates chemoinformatic-assisted drug optimization and state-of-the-art chemical synthesis with biotransformation to advance new product candidates into development. Founded by Gregory Verdine, PhD, Rick Klausner, MD, and WeiQing Zhou, MBA. LifeMine Therapeutics is headquartered in Cambridge, Massachusetts.
HC Bioscience is an innovator and pioneer of protein editing using context agnostic engineered tRNA. Their First in Class approach for protein editing advances beyond genome editing to direct modification of the proteome.
Transcenta is a global biotherapeutic company that fully integrates antibody-based biotherapeutics discovery, R&D and manufacture, focusing on developing innovative antibodies to help more patients. HJB and MabSpace Biosciences merged and created Transcenta.
Generate Biomedicines is a biotechnological company focusing on creating breakthrough medicines. It pioneers in the field of Generative Biology, a revolutionary approach to drug development that allows them to program protein-based modalities for the first time. Generate Biomedicines has proved that its machine-learning platform can generate new biological molecules with therapeutic value, accelerating the drug discovery process.
Singleron Biotechnologies is a developer and provider of clinical diagnosis, health management and drug development products and services. The company is dedicated to applying single cell analysis techniques and has obtained a world wide exclusive IP license from Yale University for its uniquely designed microfluidic single cell processing device, and has developed the innovative SCOPE single-cell pre-sequencing preparation system based on this microfluidic device.
Recuro Health delivers value throughout the healthcare ecosystem with an integrated digital health solution that transitions the U.S. healthcare system from a reactive, disease-focused model to a population health, outcomes approach. Digital Medical Home can be tailored to specific healthcare requirements. They offer fundamental virtual care services such as primary care, behavioral health, and urgent care.
ImmuneID is a precision immunology company using its proprietary platform to simultaneously identify and therapeutically target millions of antibody interactions that drive immune diseases.
HiberCell, Inc. is a clinical-stage biotechnology company founded in 2019 and based in New York, New York. It is focused on developing innovative therapeutics aimed at preventing cancer relapse and metastasis. The company's pipeline targets adaptive stress pathways and immune modulation to address treatment resistance, which is a significant factor in cancer-related deaths. HiberCell employs advanced artificial intelligence and machine learning techniques to analyze multi-omic and phenotypic profiles of tumors, generating insights that link this data to clinical outcomes. By doing so, HiberCell aims to enhance treatment strategies and ultimately help patients achieve longer, cancer-free lives. The company is supported by prominent investors in the biotechnology sector who share its vision of transforming the approach to metastatic cancer treatment.
Interline Therapeutics is a drug discovery platform that enables the company to map and correct dysfunctional protein communities. It uses genomics, proteomics, structural biology, and computational chemistry to map and modulate protein communities. Interline leverages recent advancements in these technologies, as well as collaborations with leading academic groups, to develop a precision medicine platform focused on three essential areas, genomics, communities, and modulators. The South San Francisco, California-located company was founded by Zach Sweeney in 2020.
Treeline Biosciences is a biotech company building transformative precision medicines for patients with cancer and other serious conditions. The company was founded in 2021 and is headquartered in Stamford, Connecticut.
Ultivue is a biotechnology company that specializes in tissue imaging, diagnostics, and multiplexing. Ultivue produces reagents that enable researchers to obtain microscopic images at an unprecedented resolution that helps to understand of biology and medicine. Ultivue's products are designed for fluorescent microscopy-based research and will eventually be valuable for clinical diagnostic use.
Vizgen is a privately held biotech company developing the next generation of spatially resolved, single-cell transcriptomics technology and toolbox. The company's patented MERFISH technology enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and detection efficiency at subcellular resolution.
Volastra Therapeutics is a biotechnology company developing novel therapies for the treatment of metastatic cancers by exploiting unique insights into chromosomal instability.
Interline Therapeutics is a drug discovery platform that enables the company to map and correct dysfunctional protein communities. It uses genomics, proteomics, structural biology, and computational chemistry to map and modulate protein communities. Interline leverages recent advancements in these technologies, as well as collaborations with leading academic groups, to develop a precision medicine platform focused on three essential areas, genomics, communities, and modulators. The South San Francisco, California-located company was founded by Zach Sweeney in 2020.
ImmuneID is a precision immunology company using its proprietary platform to simultaneously identify and therapeutically target millions of antibody interactions that drive immune diseases.
EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before. The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.
LifeMine Therapeutics combines genomics with AI and synthetic biology to discover and develop a pipeline of novel medicines. LifeMine’s Avatar-Rx platform integrates high-throughput microbiology, data science and machine learning, genome engineering, and automation technologies to search the fungal biosphere for novel GEMs having a predetermined target and biological function. The platform integrates chemoinformatic-assisted drug optimization and state-of-the-art chemical synthesis with biotransformation to advance new product candidates into development. Founded by Gregory Verdine, PhD, Rick Klausner, MD, and WeiQing Zhou, MBA. LifeMine Therapeutics is headquartered in Cambridge, Massachusetts.
Altos Labs is a biotechnology company focused on cellular rejuvenation programming to restore cell health and resilience, with the goal of reversing disease to transform medicine. The company comprises a community of leading scientists, clinicians, and leaders from both academia and industry working together towards this common mission. Altos has operations in the San Francisco Bay Area and San Diego, and in Cambridge, UK, with significant collaborations in Japan.
Encodia provides in-depth information on cellular processes to enable personalized medicine. Our technology reverse translates peptide sequence information into a DNA library. This means scientists can scale their research more easily to accelerate novel approaches to our most challenging diseases. Encodia was established on January 1, 2015 in San Diego, California.
Remix Therapeutics is a biotechnology business that is working on developing small-molecule medicines to reprogram ribonucleic acid processing and cure disease in novel ways. The company's medicines aid in the identification of patterns in ribonucleic acid processing and their application to control gene expression in order to change the way genes are read from the genome, correcting, enhancing, or eliminating the gene message, allowing healthcare practitioners to address disease causes at their source.
SciNeuro Pharmaceuticals is a clinical-stage biotechnology company focused on developing groundbreaking therapies for neurodegenerative diseases. Since its founding in 2020, SciNeuro has built a portfolio of pipeline programs staged from discovery to clinical development by addressing three key disease-driving mechanisms of neurodegeneration – neurovascular inflammation, proteinopathy, and immune response. The company aims to develop disease-modifying treatment options for Alzheimer’s disease, Parkinson’s disease, and other devastating CNS diseases.
Walden Biosciences is a biotechnology company focused on transforming the treatment of kidney disease. Founded by world-renowned experts in renal disease, Walden is applying its unique, systems-based approach to address the intersection between the pathology and biology of kidney disease.
Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies.
Dewpoint Therapeutics is a biotech company developing a drug platform that targets biomolecular condensates. Its technology uses machine-learning-based image analysis tools for visualizing condensates and offers an engine for genetically linked condensatopathy which is a collection of engineered cell lines with trackable condensates to prevent harmful protein sequestration, helping healthcare providers to have access to new therapies to address unmet needs. The company was founded in 2018 and is headquartered in Boston, Massachusetts.
Singleron Biotechnologies is a developer and provider of clinical diagnosis, health management and drug development products and services. The company is dedicated to applying single cell analysis techniques and has obtained a world wide exclusive IP license from Yale University for its uniquely designed microfluidic single cell processing device, and has developed the innovative SCOPE single-cell pre-sequencing preparation system based on this microfluidic device.
Glympse Bio develops a powerful new paradigm in diagnostics to enable noninvasive and predictive monitoring of multiple human diseases. The company’s technology uses precisely engineered diagnostic agents that interrogate the body for certain disease states, and then carry the message to the urine for analysis. Glympse Bio’s platform technology was originally developed at MIT, and is founded by a team of world-renowned experts in nanomedicine and biomedical engineering.
Sana Biotechnology focuses on creating and delivering engineered cells as medicine for patients. Recent scientific advances make it possible to reprogram cells in the body or replace damaged cells and tissues, creating a new class of medicines to treat a broad array of diseases. The company is a team of scientists, clinicians and biotechnology veterans focused on creating an enduring company that makes meaningful medicines and will change the approach in treating diseases.
Bit.bio specializes in the fields of coding and biology that determine the identity of every human cell. Their mission is coding cells for health. To do so, we apply the principles of computation to biology. Bit.bio's current focus is to develop a scalable technology platform capable of producing consistent batches of every human cell. This has the potential to unlock a new generation of medicine: it will enable research and drug discovery to move on from inappropriate models and work with the cells that actually are affected by the human disease. A scalable platform of consistent cells will also be the basis for a new generation of cell and tissue therapies. To achieve our goals, we have assembled a team of pioneers in stem cells, cellular reprogramming, mathematical modeling, and cell therapy. Collaboration is at the heart of bit.bio. We are empirical, highly ambitious, and driven by a common purpose.
Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. It has been purpose-built for the task ahead, with a team of experts in cardiovascular medicine, human genetics, gene editing, delivery technologies, drug development, and commercialization.
JW Therapeutics is a developer of cell-based therapy technologies created to revolutionize cancer treatment.The company focuses on development, transformation and promotion of cell-based immunotherapies that uses chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to regulate the body's immune system, enabling doctors to save the lives of cancer patients and improve the quality of life.
Mindstrong is a virtual mental health platform that combines care, data and technology to help members do better, feel better & stay better. They offer mental health care with the strength to tackle anything and have helped thousands of members grow and improve their mental health— including those with serious mental illness.
CERo Therapeutics, Inc. is a new cellular immunotherapy company. We have created a hybrid platform that integrates innate and adaptive programs to eliminate disease.
Volastra Therapeutics is a biotechnology company developing novel therapies for the treatment of metastatic cancers by exploiting unique insights into chromosomal instability.
Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies.
Transcenta is a global biotherapeutic company that fully integrates antibody-based biotherapeutics discovery, R&D and manufacture, focusing on developing innovative antibodies to help more patients. HJB and MabSpace Biosciences merged and created Transcenta.
Epirium Bio is a biopharmaceutical company based in San Diego, is developing a small molecule platform targeting improvements in muscle strength, tissue regeneration, and mitochondrial function.
EGenesis is a biotechnology company developing solid organ and therapeutic cell transplantation to treat diseases. It offers gene editing and genome engineering platform to develop human-compatible organs, tissues, and cells, aiming to provide an alternative solution to the global organ shortage.
Boundless Bio is a company that develops novel cancer therapeutics intended to understand and treat untraceable cancers. It aims to be the biopharma company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable cancers.
One BioMed is a molecular life science company. They provide innovation for transforming human health through biomedical research, products, and testing. Their products include DNA cartridge kits and RNA cartridge kits.
Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad range of severe genetic disorders. The company's therapy pipeline addresses devastating genetic and acquired disorders spanning multiple disease pathways including neurocircuitry, metabolic disorders, neurodegeneration and cardiovascular disease, enabling medical practitioners to treat patients and improve their lives.
Ultivue is a biotechnology company that specializes in tissue imaging, diagnostics, and multiplexing. Ultivue produces reagents that enable researchers to obtain microscopic images at an unprecedented resolution that helps to understand of biology and medicine. Ultivue's products are designed for fluorescent microscopy-based research and will eventually be valuable for clinical diagnostic use.
BlackThorn Therapeutics operator of a clinical-stage biopharmaceutical company intended to develop precision medicine for disorders of the central nervous system (CNS) based on advances in computational and clinical neuroscience. The company leverages a deep understanding of brain and behavior relationships that seeks to overcome historic challenges in drug discovery and development by targeting dysfunctional brain circuits. Its proprietary computational platform, the company seeks to identify novel targets, small molecule drug candidates and biologically-based patient subgroups most likely to respond to treatment.
Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. It has been purpose-built for the task ahead, with a team of experts in cardiovascular medicine, human genetics, gene editing, delivery technologies, drug development, and commercialization.
Vividion Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing therapeutics to address significant unmet medical needs. The company utilizes a novel platform for proteome-wide small molecule drug discovery, which combines proteomic techniques and synthetic chemistry to enhance drug selectivity and broaden the range of druggable proteins. Originating from research at The Scripps Research Institute, Vividion's technology enables the creation of detailed drug interaction maps, facilitating simultaneous target engagement and comprehensive selectivity profiling. By advancing its innovative synthetic and proteomic chemistry approaches, Vividion aims to deliver transformative treatments for patients with serious illnesses.
Beam Therapeutics is a biotechnology company engaged in creating genetic medicines based on its base editing technology. It is pioneering the use of base editing, a potential new class of precision genetic medicines, with a vision of providing life-long cures to patients suffering from serious diseases. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the dna.
Transcenta is a global biotherapeutic company that fully integrates antibody-based biotherapeutics discovery, R&D and manufacture, focusing on developing innovative antibodies to help more patients. HJB and MabSpace Biosciences merged and created Transcenta.
Sana Biotechnology focuses on creating and delivering engineered cells as medicine for patients. Recent scientific advances make it possible to reprogram cells in the body or replace damaged cells and tissues, creating a new class of medicines to treat a broad array of diseases. The company is a team of scientists, clinicians and biotechnology veterans focused on creating an enduring company that makes meaningful medicines and will change the approach in treating diseases.
Vir Biotechnology is a commercial-stage immunology company developing therapeutic products to treat and prevent serious infectious diseases. The company brings together cutting-edge innovations with scientific expertise and management. It seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. Vir Biotechnology also focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company four current technology platforms are designed to, either individually or in combination, stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Their vision is that one day, diseases like hepatitis B, influenza A, HIV, and tuberculosis become a thing of the past.
Lyell is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. Lyell focuses on addressing what it believes are the primary barriers that limit consistent, reliable and curative responses with adoptive T cell therapy: T cell exhaustion and loss of durable stemness, which includes proliferative capacity, ability to self-renew and ability to differentiate and eliminate solid tumors. Lyell is applying its proprietary ex vivo genetic and epigenetic reprogramming technology platforms, Gen-R and Epi-R, to address these barriers in order to develop new medicines with improved, durable, and potentially curative clinical outcomes.
Glympse Bio develops a powerful new paradigm in diagnostics to enable noninvasive and predictive monitoring of multiple human diseases. The company’s technology uses precisely engineered diagnostic agents that interrogate the body for certain disease states, and then carry the message to the urine for analysis. Glympse Bio’s platform technology was originally developed at MIT, and is founded by a team of world-renowned experts in nanomedicine and biomedical engineering.
KSQ Therapeutics is pioneering High-Confidence Drug Development: a fundamentally new approach to R&D where the majority of the de-risking work is done prior to the generation of therapeutic drug candidates. Powered by our proprietary CRISPRomics™ drug discovery engine, their team has elucidated the function that each human gene plays in multiple diseases, providing a unique and more comprehensive understanding of disease biology. The quality of these insights enables their scientists to rapidly identify and validate high-confidence, patient-tailored, novel drug targets and then focus their collective efforts on the development of medicines with the greatest potential to impact the lives of patients. KSQ has initiated a pipeline of preclinical discovery programs and was founded in 2015.
OncoResponse Inc. is an immuno-oncology company based in Houston, Texas, focused on discovering new cancer immunotherapies and therapeutic antibodies. The company collaborates with MD Anderson Cancer Center to utilize the I-STAR™ platform, which analyzes the human memory B-cell repertoire of patients who have demonstrated exceptional responses to immunotherapy, referred to as "Elite Responders." By studying these patients, OncoResponse aims to harness the human immune system to identify fully human monoclonal antibodies and novel targets. This approach is intended to facilitate the development of innovative antibody-derived therapeutics for cancer treatment.
Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. Founded by the former Receptos executive team, Gossamer Bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology.
Qihan Biotech is a biomedical company based on genetic technology. Kaixin Bio ’s mission is to create a new world where patients do n’t have to wait for organ transplants. We are committed to using the world's advanced gene editing technology to produce safe and effective cells, tissues and organs that can be used for human transplantation, and to solve the serious shortage of organ transplant donors in China and the world.
AgBiome, LLC is a biotechnology company based in Durham, North Carolina, that focuses on developing innovative biological products for the agriculture industry. Founded in 2012, AgBiome utilizes advanced genomics and screening technologies to identify plant-associated microbes that enhance plant health, pest resistance, and crop yields. The company manufactures fungicides to protect crops from soil-borne and foliar diseases while also employing a platform that captures and screens diverse microbes for their effectiveness against insects, diseases, and nematodes. AgBiome collaborates with leading agricultural firms to accelerate its discovery process and deliver solutions that address critical challenges in global food production. With a workforce of approximately 87 employees and a state-of-the-art laboratory and greenhouse facility in the Research Triangle Park, AgBiome aims to provide sustainable and effective solutions for farmers facing significant agricultural issues.
Mindstrong is a virtual mental health platform that combines care, data and technology to help members do better, feel better & stay better. They offer mental health care with the strength to tackle anything and have helped thousands of members grow and improve their mental health— including those with serious mental illness.
Hangzhou Just Biotherapeutics is a comprehensive high-tech design company dedicated to accelerating the development of bio-medicine and significantly reducing manufacturing costs. Their core strengths are molecular design, process design, drug product design and manufacturing plant design.
Cytrellis Biosystems is a clinical stage medical technology company that designs and develops medical device for dermatology, scar reduction, and aesthetic medicine. Its devices are designed to remove sagging skin associated with aging without surgery or scarring, providing aesthetic practitioners an unprecedented ability to improve age related changes in skin. Cytrellis Biosystems was founded in 2011 and is based in Boston, Massachusetts.
Brii Biosciences is a developer of bio-pharmaceutical medicines intended to provide medical solutions to Chinese patients to fulfill their health and treatment needs. The company's medicines focuses on infectious disease drug development and commercialization in China and leverage technology and data to drive improvements to the Chinese healthcare system and outcomes for patients, enabling patients to get access to better treatments and cures for life-threatening diseases.
Beam Therapeutics is a biotechnology company engaged in creating genetic medicines based on its base editing technology. It is pioneering the use of base editing, a potential new class of precision genetic medicines, with a vision of providing life-long cures to patients suffering from serious diseases. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the dna.
Ultivue is a biotechnology company that specializes in tissue imaging, diagnostics, and multiplexing. Ultivue produces reagents that enable researchers to obtain microscopic images at an unprecedented resolution that helps to understand of biology and medicine. Ultivue's products are designed for fluorescent microscopy-based research and will eventually be valuable for clinical diagnostic use.
Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. Founded by the former Receptos executive team, Gossamer Bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology.
Scholar Rock is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company's newly elucidated understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. They believe this approach, acting in the disease microenvironment, avoids the historical challenges associated with inhibiting growth factors for therapeutic effect. We believe our focus on biologically validated growth factors may facilitate a more efficient development path. The company is advancing its lead product candidate, SRK-015, a selective first-in-class inhibitor of the activation of the growth factor myostatin in skeletal muscle, into clinical development for the treatment of spinal muscular atrophy, or SMA. They expect to initiate a Phase 1 clinical trial in the second quarter of 2018. Utilizing its proprietary platform, they are also creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including other neuromuscular disorders, cancer, fibrosis, and anemia.
Biopalette is a operator of a platform intended to offer gene-editing techniques. Bio Palette plans to develop our business in three fields, classified based on the type of cells targeted for genome editing.
Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.
KSQ Therapeutics is pioneering High-Confidence Drug Development: a fundamentally new approach to R&D where the majority of the de-risking work is done prior to the generation of therapeutic drug candidates. Powered by our proprietary CRISPRomics™ drug discovery engine, their team has elucidated the function that each human gene plays in multiple diseases, providing a unique and more comprehensive understanding of disease biology. The quality of these insights enables their scientists to rapidly identify and validate high-confidence, patient-tailored, novel drug targets and then focus their collective efforts on the development of medicines with the greatest potential to impact the lives of patients. KSQ has initiated a pipeline of preclinical discovery programs and was founded in 2015.
LifeMine Therapeutics combines genomics with AI and synthetic biology to discover and develop a pipeline of novel medicines. LifeMine’s Avatar-Rx platform integrates high-throughput microbiology, data science and machine learning, genome engineering, and automation technologies to search the fungal biosphere for novel GEMs having a predetermined target and biological function. The platform integrates chemoinformatic-assisted drug optimization and state-of-the-art chemical synthesis with biotransformation to advance new product candidates into development. Founded by Gregory Verdine, PhD, Rick Klausner, MD, and WeiQing Zhou, MBA. LifeMine Therapeutics is headquartered in Cambridge, Massachusetts.
Hangzhou Just Biotherapeutics is a comprehensive high-tech design company dedicated to accelerating the development of bio-medicine and significantly reducing manufacturing costs. Their core strengths are molecular design, process design, drug product design and manufacturing plant design.
Mindstrong is a virtual mental health platform that combines care, data and technology to help members do better, feel better & stay better. They offer mental health care with the strength to tackle anything and have helped thousands of members grow and improve their mental health— including those with serious mental illness.
Arbor Biotechnologies is an operator of a bio-discovery company intended to provide human diagnostic development services. The company's platform employs a diverse set of technologies and techniques including artificial intelligence, genome sequencing, gene synthesis, and high-throughput screening, enabling drug developers to accelerate the discovery of proteins for improving human health and sustainability.
Biopalette is a operator of a platform intended to offer gene-editing techniques. Bio Palette plans to develop our business in three fields, classified based on the type of cells targeted for genome editing.
EGenesis is a biotechnology company developing solid organ and therapeutic cell transplantation to treat diseases. It offers gene editing and genome engineering platform to develop human-compatible organs, tissues, and cells, aiming to provide an alternative solution to the global organ shortage.
Grail develops a pan-cancer screening test designed to detect cancers at an early stage. Its pan-cancer screening test measures circulating nucleic acids in blood using high-intensity sequencing, population-scale clinical trials, enabling doctors to develop blood tests for early-stage cancer detection. The company was founded in 2016 by Alex Aravanis and Jeff Huber in Menlo Park, California.
Vividion Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing therapeutics to address significant unmet medical needs. The company utilizes a novel platform for proteome-wide small molecule drug discovery, which combines proteomic techniques and synthetic chemistry to enhance drug selectivity and broaden the range of druggable proteins. Originating from research at The Scripps Research Institute, Vividion's technology enables the creation of detailed drug interaction maps, facilitating simultaneous target engagement and comprehensive selectivity profiling. By advancing its innovative synthetic and proteomic chemistry approaches, Vividion aims to deliver transformative treatments for patients with serious illnesses.
Vir Biotechnology is a commercial-stage immunology company developing therapeutic products to treat and prevent serious infectious diseases. The company brings together cutting-edge innovations with scientific expertise and management. It seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. Vir Biotechnology also focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company four current technology platforms are designed to, either individually or in combination, stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Their vision is that one day, diseases like hepatitis B, influenza A, HIV, and tuberculosis become a thing of the past.
ApoGen Biotechnologies, Inc. is focused on the development of new class of therapeutics targeting drivers of cancer genomic mutation.As the arsenal of available cancer therapies has grown and evolved from cytotoxic chemotherapy to targeted therapy to immunotherapy, one fact has unfortunately remained constant nearly all cancer drug therapies eventually fail due to the development of drug resistance. Mutation of cellular DNA is central to the formation of cancer, and chronic mutation of the cancer genome is a primary cause of cancer evolution and drug resistance, resulting in ineffective therapy, cancer recurrence and metastasis, and decreased overall survival.
Unity Biotechnology designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells; and designs senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected.
Genomics Medicine Ireland is an Irish life sciences company leading a large-scale research study across Ireland looking at the human genome to examine the relationship between genetics, health and disease.
BlackThorn Therapeutics operator of a clinical-stage biopharmaceutical company intended to develop precision medicine for disorders of the central nervous system (CNS) based on advances in computational and clinical neuroscience. The company leverages a deep understanding of brain and behavior relationships that seeks to overcome historic challenges in drug discovery and development by targeting dysfunctional brain circuits. Its proprietary computational platform, the company seeks to identify novel targets, small molecule drug candidates and biologically-based patient subgroups most likely to respond to treatment.
Denali Therapeutics is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, ALS and others. Denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. Denali is rigorously pursuing a science-driven approach to translational medicine and clinical development.
Hangzhou Just Biotherapeutics is a comprehensive high-tech design company dedicated to accelerating the development of bio-medicine and significantly reducing manufacturing costs. Their core strengths are molecular design, process design, drug product design and manufacturing plant design.
Just Evotec Biologics was founded in 2014 and acquired by Evotec in 2019. The company has an intense focus on the design of innovative and integrated technologies to accelerate the development of biotherapeutics and reduce their manufacturing cost. Core strengths include antibody discovery, molecular design, process and product design and manufacturing plant design.